[{"address1": "9920 Pacific Heights Boulevard", "address2": "Suite 350", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 704 4660", "website": "https://www.vikingtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR\u00df), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR\u00df for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.", "fullTimeEmployees": 48, "companyOfficers": [{"maxAge": 1, "name": "Dr. Brian  Lian Ph.D.", "age": 58, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 1193748, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gregory S. Zante CPA, CPA", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 713000, "exercisedValue": 20395892, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Marianne  Mancini", "age": 59, "title": "Chief Operating Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 735000, "exercisedValue": 8888907, "unexercisedValue": 636903}, {"maxAge": 1, "name": "Mr. Michael  Morneau", "age": 59, "title": "Vice President of Finance & Administration", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 375333, "exercisedValue": 0, "unexercisedValue": 490518}, {"maxAge": 1, "name": "Dr. Geoffrey E. Barker Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 25.74, "open": 25.83, "dayLow": 24.8, "dayHigh": 25.87, "regularMarketPreviousClose": 25.74, "regularMarketOpen": 25.83, "regularMarketDayLow": 24.8, "regularMarketDayHigh": 25.87, "payoutRatio": 0.0, "beta": 0.722, "forwardPE": -16.430464, "volume": 4037024, "regularMarketVolume": 4037024, "averageVolume": 5975479, "averageVolume10days": 4738390, "averageDailyVolume10Day": 4738390, "bid": 24.76, "ask": 24.89, "bidSize": 24, "askSize": 12, "marketCap": 2789760512, "fiftyTwoWeekLow": 18.92, "fiftyTwoWeekHigh": 81.73, "fiftyDayAverage": 31.0406, "twoHundredDayAverage": 31.8038, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 4772673024, "profitMargins": 0.0, "floatShares": 219960335, "sharesOutstanding": 112445000, "sharesShort": 26677306, "sharesShortPriorMonth": 28698835, "sharesShortPreviousMonthDate": 1753920000, "dateShortInterest": 1756425600, "sharesPercentSharesOut": 0.23719999, "heldPercentInsiders": 0.021459999, "heldPercentInstitutions": 0.6838, "shortRatio": 3.05, "shortPercentOfFloat": 0.2846, "impliedSharesOutstanding": 112445000, "bookValue": 7.081, "priceToBook": 3.5037425, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -171547008, "trailingEps": -1.54, "forwardEps": -1.51, "52WeekChange": -0.6302533, "SandP52WeekChange": 0.16885936, "quoteType": "EQUITY", "currentPrice": 24.81, "targetHighPrice": 125.0, "targetLowPrice": 33.0, "targetMeanPrice": 92.29412, "targetMedianPrice": 98.0, "recommendationMean": 1.47059, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 17, "totalCash": 807724032, "totalCashPerShare": 3.592, "totalDebt": 878000, "quickRatio": 25.257, "currentRatio": 25.86, "debtToEquity": 0.11, "returnOnAssets": -0.14991, "returnOnEquity": -0.19989, "freeCashflow": -102103128, "operatingCashflow": -152535008, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "VKTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1757721480, "regularMarketTime": 1757707200, "exchange": "NCM", "messageBoardId": "finmb_246791410", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -3.61305, "regularMarketPrice": 24.81, "shortName": "Viking Therapeutics, Inc.", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 5975479, "fiftyTwoWeekLowChange": 5.8899994, "fiftyTwoWeekLowChangePercent": 0.31131074, "fiftyTwoWeekRange": "18.92 - 81.73", "fiftyTwoWeekHighChange": -56.920006, "fiftyTwoWeekHighChangePercent": -0.69643956, "fiftyTwoWeekChangePercent": -63.02533, "earningsTimestamp": 1753300800, "earningsTimestampStart": 1761163200, "earningsTimestampEnd": 1761163200, "earningsCallTimestampStart": 1753302600, "earningsCallTimestampEnd": 1753302600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.54, "epsForward": -1.51, "epsCurrentYear": -2.34143, "priceEpsCurrentYear": -10.596088, "fiftyDayAverageChange": -6.2306004, "fiftyDayAverageChangePercent": -0.20072423, "twoHundredDayAverageChange": -6.993801, "twoHundredDayAverageChangePercent": -0.21990457, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.5 - Strong Buy", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1430227800000, "postMarketChangePercent": 0.403472, "postMarketPrice": 24.9101, "postMarketChange": 0.100101, "regularMarketChange": -0.93, "regularMarketDayRange": "24.8 - 25.87", "longName": "Viking Therapeutics, Inc.", "cryptoTradeable": false, "marketState": "CLOSED", "displayName": "Viking Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-09-13"}]